ClinicalTrials.gg
RecruitingNCT07118631Updated Aug 12, 2025

Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding

An observational study in Arteriovenous Malformation and Bleeding, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Primary conditionIntracranial Arteriovenous MalformationsRegistry: Arteriovenous MalformationsReclassifiedWhy we changed it
Registry
Arteriovenous Malformations — the first condition term the registry derived for this study.
ClinicalTrials.gg
Intracranial Arteriovenous Malformations
Why
  1. The study's title name Intracranial Arteriovenous Malformations, a narrower term within Arteriovenous Malformations.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing Tiantan Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
162
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Intracranial Arteriovenous Malformations with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Arteriovenous Malformations · China.

Started
2025
the only one that year
Observational
7 of 13
3 open now
Registered
11th of 13
by date
Lead sponsor
6 of 13
Beijing Tiantan Hospital

Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, this one is the only one that started in 2025, is one of 7 observational ones, and was the 11th registered.

Intracranial Arteriovenous Malformations

43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.

Browse Intracranial Arteriovenous Malformations studies →

Open to participants now

4 of the 13 studies in Intracranial Arteriovenous Malformations with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 13 Intracranial Arteriovenous Malformations studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Intracranial Arteriovenous Malformations with a site in China, or all of them as a file.
02

Study summary

Cerebral arteriovenous malformation (AVM) is the leading cause of brain hemorrhage in young adults, characterized by sudden onset and rapid progression. The hybrid neurosurgical operating room is a diagnostic and therapeutic platform that integrates neurointervention and microneurosurgery, offering advantages such as one-stop rapid treatment and multimodal therapeutic approaches.

This study aims to focus on patients with acute cerebral AVM-related hemorrhage through a multicenter, prospective, registry-based research approach. In the hybrid neurosurgical operating room, emergency cerebral angiography, neurointerventional embolization, microsurgical resection of the vascular malformation, or minimally invasive hematoma evacuation will be performed to explore the indications and advantages of the hybrid neurosurgical operating platform in emergency AVM hemorrhage management. The study seeks to establish standardized diagnostic and treatment protocols and operational workflows for emergency AVM hemorrhage management in the hybrid operating room. Through continuous quality improvement, the study aims to further reduce patient morbidity and mortality.

This research will not only enhance the diagnostic and therapeutic level of cerebral AVM-related hemorrhage and improve patient outcomes but also effectively reduce medical costs and societal burdens.

03

Conditions studied

  • Arteriovenous Malformation
  • Bleeding

Keywords

  • Cerebral hemorrhage
  • cerebral arteriovenous malformation
  • hybrid surgery
  • functional prognosis
  • quality improvement system
04

In context

Intracranial Arteriovenous Malformations Reclassified

43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.

This study's planned enrollment of 162 is above the median of 140 across 25 observational studies indexed under Intracranial Arteriovenous Malformations.

Browse Intracranial Arteriovenous Malformations studies →

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.

Compared within Intracranial Arteriovenous Malformations, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arteriovenous Malformations. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with mergency cerebral arteriovenous malformation bleeding

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Head CT confirmed cerebral hemorrhage, with indications for emergency surgery
  • Head CTA suggested that the responsible lesion may be cerebral arteriovenous malformation
  • Spetzler-Martin classification 1 to 4; Cerebral arteriovenous malformation Spetzler-Martin classification is as follows: ① Nidus size: small (\<3 cm) is scored as 1 point, medium (3 cm\~6 cm) is scored as 2 points, and large (≥6 cm) is scored as 3 points; ② Adjacent brain functional areas: 0 points for non-functional areas, 1 point for functional areas; ③ Drainage veins: 0 points for superficial veins, 1 point for deep veins);
  • Aged 18 to 70 years old, with systemic conditions that can tolerate surgery;
  • Agree to surgical treatment and sign an form.

Exclusion criteria

Exclusion Criteria:

  • Consciousness disorder due to serious underlying diseases
  • Patients or family members who refuse surgery
  • Perinatal and pregnancy patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
162 participants (estimated)
Patient registry
No

Groups and cohorts

  • Hybrid surgery cohort

    After patients were enrolled, they were admitted to the hybrid operating room for DSA to confirm the diagnosis. If the patient meets the surgical indications, one-stop treatment with composite surgery will be performed. During the operation, the treatment plan is determined based on the characteristics of the malformation group, including simple embolization, partial embolization, auxiliary embolization for arteriovenous malformation resection, and the target area and proportion of embolization. For those who need craniotomy, the hematoma is removed during the operation and the brain arteriovenous malformation is removed under a microscope. Intraoperative ultrasound assists in locating the location, boundaries and residue of the malformation. Head DSA was reviewed immediately after surgery. Further clarify whether the lesions are completely removed. If the lesion remains, immediate surgical treatment and subsequent DSA review will be perfor

07

What researchers measure

Primary outcomes

  1. Neurological outcomes

    modified rankin scale (mRS), The scale runs from 0-6. Higher scores mean a worse outcome

    Time frame: 2 weeks, 3 months, 6 months after surgery

Secondary outcomes

  1. surgical information

    Time frame: pre-surgery, during the surgery, perioperatively immediately after the surgery

  2. Complications

    Time frame: 2 weeks, 3 months, 6 months after surgery

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 12, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
Jan 31, 2028
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07118631
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Apr 1, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Aug 12, 2025

Study contacts

Yuming Jiao, MD
Contact
shengxiongyuming@163.com
86-15010108242

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion